← Back to Screener
Vir Biotechnology, Inc. Common Stock (VIR)
Price$8.65
Value ScoreB
Growth ScoreC
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)26.81%
Price vs S&P 500 (4W)-5.14%
VGM Score58.79
Market Capitalization$1.48B
All Metrics
Book Value / Share (Quarterly)$5.04
P/TBV (Annual)1.11x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-65.12%
Cash Flow / Share (Quarterly)$-2.79
Price vs S&P 500 (YTD)35.29%
Gross Margin (TTM)99.96%
Net Profit Margin (TTM)-638.87%
EPS (TTM)$-3.16
10-Day Avg Trading Volume1.75M
EPS Excl Extra (TTM)$-3.16
Revenue Growth (5Y)-2.14%
EPS (Annual)$-3.16
ROI (Annual)-57.23%
Gross Margin (Annual)99.96%
Net Profit Margin (5Y Avg)-395.16%
Cash / Share (Quarterly)$2.95
Revenue Growth QoQ (YoY)417.78%
ROA (Last FY)-43.68%
Revenue Growth TTM (YoY)-7.61%
EBITD / Share (TTM)$-3.38
ROE (5Y Avg)-15.91%
Operating Margin (TTM)-699.18%
Cash Flow / Share (Annual)$-2.84
P/B Ratio1.82x
P/B Ratio (Quarterly)1.78x
Net Income / Employee (Annual)$-1,193,400
EV / Revenue (TTM)17.58x
Net Interest Coverage (TTM)10.09x
ROA (TTM)-38.74%
EV / EBITDA (TTM)1.44x
EPS Incl Extra (Annual)$-3.16
Current Ratio (Annual)5.54x
Quick Ratio (Quarterly)6.55x
3-Month Avg Trading Volume2.91M
52-Week Price Return67.96%
EV / Free Cash Flow (Annual)-2.40x
Revenue / Employee (TTM)$186,800
Tangible BV / Share (Quarterly)$4.99
P/S Ratio (Annual)21.57x
Asset Turnover (Annual)0.07x
52-Week High$11.66
Operating Margin (5Y Avg)-438.90%
EPS Excl Extra (Annual)$-3.16
CapEx CAGR (5Y)-5.76%
Tangible BV CAGR (5Y)2.09%
26-Week Price Return34.74%
Quick Ratio (Annual)5.09x
13-Week Price Return-4.95%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.11x
Enterprise Value$1.20B
Revenue / Share Growth (5Y)-5.04%
Asset Turnover (TTM)0.06x
Book Value / Share Growth (5Y)-0.50%
Revenue / Employee (Annual)$186,800
Pretax Margin (Annual)-638.56%
Cash / Share (Annual)$3.35
3-Month Return Std Dev53.00%
Gross Margin (5Y Avg)96.11%
Net Income / Employee (TTM)$-1,193,400
ROE (Last FY)-57.23%
Net Interest Coverage (Annual)11.83x
EPS Basic Excl Extra (Annual)$-3.16
P/FCF (TTM)0.93x
Receivables Turnover (TTM)4.18x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.16
Receivables Turnover (Annual)4.18x
ROI (TTM)-49.31%
P/S Ratio (TTM)21.57x
Pretax Margin (5Y Avg)-395.11%
Revenue / Share (Annual)$0.49
Tangible BV / Share (Annual)$5.43
Price vs S&P 500 (52W)43.60%
Year-to-Date Return43.45%
5-Day Price Return-4.21%
EPS Normalized (Annual)$-3.16
ROA (5Y Avg)-13.52%
Net Profit Margin (Annual)-638.87%
Month-to-Date Return-9.33%
Cash Flow / Share (TTM)$-4.36
EBITD / Share (Annual)$-3.46
Operating Margin (Annual)-699.18%
ROI (5Y Avg)-15.91%
EPS Basic Excl Extra (TTM)$-3.16
P/TBV (Quarterly)1.79x
P/B Ratio (Annual)1.10x
Pretax Margin (TTM)-638.56%
Book Value / Share (Annual)$5.49
Price vs S&P 500 (13W)-13.20%
Beta1.70x
P/FCF (Annual)0.93x
Revenue / Share (TTM)$0.49
ROE (TTM)-49.31%
52-Week Low$4.16
vGradeB
gGradeC
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.85est. -0.10
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.14
4.14
4.21
4.21
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
VIRVir Biotechnology, Inc. Common Stock | B | C | B | $8.65 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Vir Biotechnology is a clinical-stage biopharmaceutical company developing immunology-focused medicines for serious infectious diseases and cancer. The company leverages proprietary technologies including antibody engineering, an AI discovery platform (dAIsY), and a masking platform (PRO-XTEN) to develop a pipeline that includes therapies for hepatitis delta virus and HIV, as well as multiple solid tumor programs. Currently, the company generates revenue primarily through licensing agreements and research grants while advancing its clinical development programs.